An overview of our requirements is outlined below. For more information and proposal submission instructions, refer to the RFP main document. Additional instructions may get published in bulletins.
Canada’s federal, provincial, and territorial health care decision makers rely on CDA-AMC to provide them with credible, impartial advice and evidence-based information about the effectiveness of drugs and other health technologies. Our scope includes health technology assessment, the clinical and cost-effectiveness of new drugs, and best practices in drug prescribing and use in Canada.
Project 1 – Compensation Review
Our current compensation methodology identifies the maximum of our salary ranges as the 50th percentile of the market we compare ourselves to. Salary increases for employees have been historically applied consistently, and no variable pay structure is currently in place for the majority of our workforce.
We are seeking proposals to conduct a comprehensive compensation review. As part of our commitment to attracting and retaining top talent, it is vital to ensure that our compensation practices are competitive, equitable, and aligned with both industry standards and our organizational values. The organization’s last compensation review was conducted in our 2022-2023 fiscal year.
Project 2 – Pay Equity Maintenance Review
Canada’s Drug Agency is subject to Part I of the Pay Equity Act (Ontario). As the organization has evolved over the last several years, there is an opportunity to reassess our pay equity positioning and to ensure compliance with the Act. Our workforce is comprised of approximately 300 employees and approximately 150 unique jobs.
